2013
DOI: 10.12998/wjcc.v1.i7.227
|View full text |Cite
|
Sign up to set email alerts
|

Unusual case of insitu (intracystic) papillary carcinoma of breast

Abstract: The term "intracystic papillary ductal carcinoma in situ", has recently changed and is now more appropriately referred to as "intracystic papillary carcinoma'' constituting only 0.5% to 1% of all breast cancers. Herein, we discuss an unusual case of intracystic insitu papillary carcinoma of breast in a postmenopausal woman, the diagnosis of which was made on histopathology and confirmed by immunohistochemistry. Patient responded well to postoperative adjuvant radiotherapy without any recurrence, thereby preven… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
1
0
1

Year Published

2014
2014
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 13 publications
0
1
0
1
Order By: Relevance
“…Hormone therapy is mainly prescribed to reduce the risk of local recurrence in case of hormone receptors positive, we put our patient on tamoxifen. Despite these general principles, the Optimal treatment of CPIK remains controversial [16].…”
Section: Discussionmentioning
confidence: 99%
“…Hormone therapy is mainly prescribed to reduce the risk of local recurrence in case of hormone receptors positive, we put our patient on tamoxifen. Despite these general principles, the Optimal treatment of CPIK remains controversial [16].…”
Section: Discussionmentioning
confidence: 99%
“…L'hormonothérapie adjuvante principalement avec le tamoxifène devrait être prescrite pour réduire le risque de récidive locale en cas de récepteurs hormonaux positifs. En dépit de ces principes généraux, le traitement optimal du CPIK reste controversé [ 6 ].…”
Section: Discussionunclassified
“…La chimiothérapie n'est pas obligatoire pour son faible potentiel invasif. L'hormonothérapie adjuvante devrait être prescrite pour réduire le risque de récidive locale en cas de récepteurs hormonaux positifs (Ingle SB et al, 2013).…”
Section: Observationunclassified